Healthcare

Dragonfly, whose co-founders include MIT and UC Berkeley faculty, has boosted its total financing to $300m in round of undisclosed size led by Fidelity.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

University of Wisconsin-Madison gene medicine developer Design Therapeutics has attracted SR One for its series A round.

UC Berkeley's Nurix Therapeutics will use the capital to prepare two protein modulation-based immuno-oncology drugs for the clinic.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.